HiCisco (002653) announced on the evening of March 31 that the company recently received the innovative drug HSK16149 capsule “Drug Clinical Trial Approval Notice” issued by the State Drug Administration to treat central nervous system pathological pain. HSK16149 capsules submitted NDA applications for diabetic peripheral neuralgia indications in October 2022, and also submitted NDA applications for post-herpes zoster neuralgia indications in September 2023. Both are currently undergoing technical reviews.
海思科：获得HSK16149胶囊新适应症药物临床试验批准通知书
HiCisco: Obtaining an Approval Notice for Clinical Trials of HSK16149 Capsules for New Indications
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.